This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen de acción 0IF
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Competidores de LogicBio Therapeutics, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | €1.87 |
| 52 Week High | €2.84 |
| 52 Week Low | €0.26 |
| Beta | 4.62 |
| 1 Month Change | -10.10% |
| 3 Month Change | 274.00% |
| 1 Year Change | -25.20% |
| 3 Year Change | -76.33% |
| 5 Year Change | n/a |
| Change since IPO | -71.49% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| 0IF | DE Biotechs | Mercado DE | |
|---|---|---|---|
| 7D | -6.0% | 2.1% | -1.0% |
| 1Y | -25.2% | -22.2% | 2.0% |
Rentabilidad vs. Industria: 0IF underperformed the German Biotechs industry which returned 1.4% over the past year.
Rentabilidad vs. Mercado: 0IF underperformed the German Market which returned -21.6% over the past year.
Volatilidad de los precios
| 0IF volatility | |
|---|---|
| 0IF Average Weekly Movement | 208.8% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: 0IF's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: 0IF's weekly volatility has increased from 102% to 209% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2014 | 62 | Fred Chereau | www.logicbio.com |
Resumen de fundamentos de LogicBio Therapeutics, Inc.
| Estadísticas fundamentales de 0IF | |
|---|---|
| Capitalización bursátil | €68.23m |
| Beneficios(TTM) | -€25.61m |
| Ingresos (TTM) | €10.38m |
5.9x
Ratio precio-ventas (PS)-2.4x
Ratio precio-beneficio (PE)¿Está 0IF sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de 0IF | |
|---|---|
| Ingresos | US$10.76m |
| Coste de los ingresos | US$30.68m |
| Beneficio bruto | -US$19.92m |
| Otros gastos | US$6.62m |
| Beneficios | -US$26.54m |
Últimos beneficios comunicados
Sep 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.81 |
| Margen bruto | -185.15% |
| Margen de beneficio neto | -246.71% |
| Ratio deuda/patrimonio | 37.7% |
¿Cómo se ha desempeñado 0IF a largo plazo?
Ver rendimiento histórico y comparativa